22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases

Abstract

We have developed a B cell peptide-based Her-2/neu vaccine (HerVaxx) comprising trastuzumab’s binding site. Previous work in pre-clinical and clinical settings has shown that the vaccine reduces primary tumor growth by inducing polyclonal anti-tumor immune responses and immunological memory. Treatment with the monoclonal antibodies (mAbs) pertuzumab and trastuzumab have demonstrated remarkable success in the clinical outcome of patients with Her-2/neu-positive metastatic breast cancer. However, active immunization with B cell peptide-based vaccines can induce the production of the corresponding mAbs by the patient’s immune system.